

EMEA (Europe, Middle East and Africa) Ulcerative Colitis Immunology Drugs Market Report 2017

<https://marketpublishers.com/r/E523CB47640EN.html>

Date: December 2017

Pages: 108

Price: US\$ 4,000.00 (Single User License)

ID: E523CB47640EN

Abstracts

In this report, the EMEA Ulcerative Colitis Immunology Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Ulcerative Colitis Immunology Drugs for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Ulcerative Colitis Immunology Drugs market competition by top manufacturers/players, with Ulcerative Colitis Immunology Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

Janssen Biotech, Inc.

Bristol-Myers Squibb Company

AbbVie Inc.

UCBCares

AMGEN

Celltrion Healthcare

Biogen

Genentech USA, Inc.

ROCHE

Pfizer Inc.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

Adalimumab

Certolizumab Pegol

Tofacitinib

Etanercept

Golimumab

Abatacept

Infliximab

Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Rheumatoid Arthritis

Crohn's Disease(CD)

Ankylosing Spondylitis(AS)

Psoriasis(Ps)

Ulcerative Colitis(UC)

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Ulcerative Colitis Immunology Drugs Market Report 2017

1 ULCERATIVE COLITIS IMMUNOLOGY DRUGS OVERVIEW

1.1 Product Overview and Scope of Ulcerative Colitis Immunology Drugs

1.2 Classification of Ulcerative Colitis Immunology Drugs

1.2.1 EMEA Ulcerative Colitis Immunology Drugs Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 EMEA Ulcerative Colitis Immunology Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 Adalimumab

1.2.4 Certolizumab Pegol

1.2.5 Tofacitinib

1.2.6 Etanercept

1.2.7 Golimumab

1.2.8 Abatacept

1.2.9 Infliximab

1.2.10 Others

1.3 EMEA Ulcerative Colitis Immunology Drugs Market by Application/End Users

1.3.1 EMEA Ulcerative Colitis Immunology Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022)

1.3.2 Rheumatoid Arthritis

1.3.3 Crohn's Disease(CD)

1.3.4 Ankylosing Spondylitis(AS)

1.3.5 Psoriasis(Ps)

1.3.6 Ulcerative Colitis(UC)

1.4 EMEA Ulcerative Colitis Immunology Drugs Market by Region

1.4.1 EMEA Ulcerative Colitis Immunology Drugs Market Size (Value) Comparison by Region (2012-2022)

1.4.2 Europe Status and Prospect (2012-2022)

1.4.3 Middle East Status and Prospect (2012-2022)

1.4.4 Africa Status and Prospect (2012-2022)

1.5 EMEA Market Size (Value and Volume) of Ulcerative Colitis Immunology Drugs (2012-2022)

1.5.1 EMEA Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2022)

1.5.2 EMEA Ulcerative Colitis Immunology Drugs Revenue and Growth Rate

(2012-2022)

2 EMEA ULCERATIVE COLITIS IMMUNOLOGY DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Ulcerative Colitis Immunology Drugs Market Competition by Players/Manufacturers

2.1.1 EMEA Ulcerative Colitis Immunology Drugs Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Ulcerative Colitis Immunology Drugs Revenue and Share by Players (2012-2017)

2.1.3 EMEA Ulcerative Colitis Immunology Drugs Sale Price by Players (2012-2017)

2.2 EMEA Ulcerative Colitis Immunology Drugs (Volume and Value) by Type/Product Category

2.2.1 EMEA Ulcerative Colitis Immunology Drugs Sales and Market Share by Type (2012-2017)

2.2.2 EMEA Ulcerative Colitis Immunology Drugs Revenue and Market Share by Type (2012-2017)

2.2.3 EMEA Ulcerative Colitis Immunology Drugs Sale Price by Type (2012-2017)

2.3 EMEA Ulcerative Colitis Immunology Drugs (Volume) by Application

2.4 EMEA Ulcerative Colitis Immunology Drugs (Volume and Value) by Region

2.4.1 EMEA Ulcerative Colitis Immunology Drugs Sales and Market Share by Region (2012-2017)

2.4.2 EMEA Ulcerative Colitis Immunology Drugs Revenue and Market Share by Region (2012-2017)

2.4.3 EMEA Ulcerative Colitis Immunology Drugs Sales Price by Region (2012-2017)

3 EUROPE ULCERATIVE COLITIS IMMUNOLOGY DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Ulcerative Colitis Immunology Drugs Sales and Value (2012-2017)

3.1.1 Europe Ulcerative Colitis Immunology Drugs Sales Volume and Growth Rate (2012-2017)

3.1.2 Europe Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2012-2017)

3.2 Europe Ulcerative Colitis Immunology Drugs Sales and Market Share by Type

3.3 Europe Ulcerative Colitis Immunology Drugs Sales and Market Share by Application

3.4 Europe Ulcerative Colitis Immunology Drugs Sales Volume and Value (Revenue) by Countries

3.4.1 Europe Ulcerative Colitis Immunology Drugs Sales Volume by Countries (2012-2017)

3.4.2 Europe Ulcerative Colitis Immunology Drugs Revenue by Countries (2012-2017)

3.4.3 Germany Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

3.4.4 France Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

3.4.5 UK Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

3.4.6 Russia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

3.4.7 Italy Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

3.4.8 Benelux Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST ULCERATIVE COLITIS IMMUNOLOGY DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Ulcerative Colitis Immunology Drugs Sales and Value (2012-2017)

4.1.1 Middle East Ulcerative Colitis Immunology Drugs Sales Volume and Growth Rate (2012-2017)

4.1.2 Middle East Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2012-2017)

4.2 Middle East Ulcerative Colitis Immunology Drugs Sales and Market Share by Type

4.3 Middle East Ulcerative Colitis Immunology Drugs Sales and Market Share by Application

4.4 Middle East Ulcerative Colitis Immunology Drugs Sales Volume and Value (Revenue) by Countries

4.4.1 Middle East Ulcerative Colitis Immunology Drugs Sales Volume by Countries (2012-2017)

4.4.2 Middle East Ulcerative Colitis Immunology Drugs Revenue by Countries (2012-2017)

4.4.3 Saudi Arabia Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

4.4.4 Israel Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

4.4.5 UAE Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

4.4.6 Iran Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

5 AFRICA ULCERATIVE COLITIS IMMUNOLOGY DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Ulcerative Colitis Immunology Drugs Sales and Value (2012-2017)

5.1.1 Africa Ulcerative Colitis Immunology Drugs Sales Volume and Growth Rate (2012-2017)

5.1.2 Africa Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2012-2017)

5.2 Africa Ulcerative Colitis Immunology Drugs Sales and Market Share by Type

5.3 Africa Ulcerative Colitis Immunology Drugs Sales and Market Share by Application

5.4 Africa Ulcerative Colitis Immunology Drugs Sales Volume and Value (Revenue) by Countries

5.4.1 Africa Ulcerative Colitis Immunology Drugs Sales Volume by Countries (2012-2017)

5.4.2 Africa Ulcerative Colitis Immunology Drugs Revenue by Countries (2012-2017)

5.4.3 South Africa Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

5.4.4 Nigeria Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

5.4.5 Egypt Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

5.4.6 Algeria Ulcerative Colitis Immunology Drugs Sales and Growth Rate (2012-2017)

6 EMEA ULCERATIVE COLITIS IMMUNOLOGY DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Janssen Biotech, Inc.

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Bristol-Myers Squibb Company

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 AbbVie Inc.

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 UCBCares

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 AMGEN

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 Celltrion Healthcare

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Biogen

6.7.1 Company Basic Information, Manufacturing Base and Competitors

6.7.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Genentech USA, Inc.

6.8.1 Company Basic Information, Manufacturing Base and Competitors

- 6.8.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification
 - 6.8.2.1 Product A
 - 6.8.2.2 Product B
- 6.8.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
- 6.8.4 Main Business/Business Overview
- 6.9 ROCHE
 - 6.9.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.9.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification
 - 6.9.2.1 Product A
 - 6.9.2.2 Product B
 - 6.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
 - 6.9.4 Main Business/Business Overview
- 6.10 Pfizer Inc.
 - 6.10.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.10.2 Ulcerative Colitis Immunology Drugs Product Type, Application and Specification
 - 6.10.2.1 Product A
 - 6.10.2.2 Product B
 - 6.10.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
 - 6.10.4 Main Business/Business Overview

7 ULCERATIVE COLITIS IMMUNOLOGY DRUGS MANUFACTURING COST ANALYSIS

- 7.1 Ulcerative Colitis Immunology Drugs Key Raw Materials Analysis
 - 7.1.1 Key Raw Materials
 - 7.1.2 Price Trend of Key Raw Materials
 - 7.1.3 Key Suppliers of Raw Materials
 - 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
 - 7.2.1 Raw Materials
 - 7.2.2 Labor Cost
 - 7.2.3 Manufacturing Expenses
- 7.3 Manufacturing Process Analysis of Ulcerative Colitis Immunology Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 8.1 Ulcerative Colitis Immunology Drugs Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Ulcerative Colitis Immunology Drugs Major Manufacturers in 2016
- 8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 9.1 Marketing Channel
 - 9.1.1 Direct Marketing
 - 9.1.2 Indirect Marketing
 - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
 - 9.2.1 Pricing Strategy
 - 9.2.2 Brand Strategy
 - 9.2.3 Target Client
- 9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

- 10.1 Technology Progress/Risk
 - 10.1.1 Substitutes Threat
 - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

11 EMEA ULCERATIVE COLITIS IMMUNOLOGY DRUGS MARKET FORECAST (2017-2022)

- 11.1 EMEA Ulcerative Colitis Immunology Drugs Sales, Revenue and Price Forecast (2017-2022)
 - 11.1.1 EMEA Ulcerative Colitis Immunology Drugs Sales and Growth Rate Forecast (2017-2022)
 - 11.1.2 EMEA Ulcerative Colitis Immunology Drugs Revenue and Growth Rate Forecast (2017-2022)
 - 11.1.3 EMEA Ulcerative Colitis Immunology Drugs Price and Trend Forecast (2017-2022)
- 11.2 EMEA Ulcerative Colitis Immunology Drugs Sales, Revenue and Growth Rate

Forecast by Region (2017-2022)

11.3 Europe Ulcerative Colitis Immunology Drugs Sales, Revenue and Growth Rate

Forecast by Region (2017-2022)

11.4 Middle Eastt Ulcerative Colitis Immunology Drugs Sales, Revenue and Growth

Rate Forecast by Region (2017-2022)

11.5 Africa Ulcerative Colitis Immunology Drugs Sales, Revenue and Growth Rate

Forecast by Region (2017-2022)

11.6 EMEA Ulcerative Colitis Immunology Drugs Sales Forecast by Type (2017-2022)

11.7 EMEA Ulcerative Colitis Immunology Drugs Sales Forecast by Application
(2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Ulcerative Colitis Immunology Drugs

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Volume (K Pcs) by Type (2012-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Volume Market Share by Type (Product Category) in 2016

Figure Adalimumab Product Picture

Figure Certolizumab Pegol Product Picture

Figure Tofacitinib Product Picture

Figure Etanercept Product Picture

Figure Golimumab Product Picture

Figure Abatacept Product Picture

Figure Infliximab Product Picture

Figure Others Product Picture

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Volume (K Pcs) by Application (2012-2022)

Figure EMEA Sales Market Share of Ulcerative Colitis Immunology Drugs by Application in 2016

Figure Rheumatoid Arthritis Examples

Table Key Downstream Customer in Rheumatoid Arthritis

Figure Crohn's Disease(CD) Examples

Table Key Downstream Customer in Crohn's Disease(CD)

Figure Ankylosing Spondylitis(AS) Examples

Table Key Downstream Customer in Ankylosing Spondylitis(AS)

Figure Psoriasis(Ps) Examples

Table Key Downstream Customer in Psoriasis(Ps)

Figure Ulcerative Colitis(UC) Examples

Table Key Downstream Customer in Ulcerative Colitis(UC)

Figure EMEA Ulcerative Colitis Immunology Drugs Market Size (Million USD) by Region (2012-2022)

Figure Europe Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure Europe Ulcerative Colitis Immunology Drugs Revenue (Million USD) Status and Forecast by Countries

Figure Middle East Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure Middle East Ulcerative Colitis Immunology Drugs Revenue (Million USD) Status and Forecast by Countries

Figure Africa Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure Africa Ulcerative Colitis Immunology Drugs Revenue (Million USD) Status and Forecast by Countries

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Volume and Growth Rate (2012-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Sales Volume (K Pcs) of Major Players (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Sales Share by Players (2012-2017)

Figure 2016 Ulcerative Colitis Immunology Drugs Sales Share by Players

Figure 2017 Ulcerative Colitis Immunology Drugs Sales Share by Players

Figure EMEA Ulcerative Colitis Immunology Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Revenue (Million USD) by Players (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Revenue Share by Players (2012-2017)

Table 2016 EMEA Ulcerative Colitis Immunology Drugs Revenue Share by Players

Table 2017 EMEA Ulcerative Colitis Immunology Drugs Revenue Share by Players

Table EMEA Ulcerative Colitis Immunology Drugs Sale Price (USD/Pcs) by Players (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Market Share by Type (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Sales Share by Type (2012-2017)

Figure Sales Market Share of Ulcerative Colitis Immunology Drugs by Type (2012-2017)

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Ulcerative Colitis Immunology Drugs by Type in 2016

Table EMEA Ulcerative Colitis Immunology Drugs Sale Price (USD/Pcs) by Type (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Market Share by Application (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Sales Share by Application (2012-2017)

Figure Sales Market Share of Ulcerative Colitis Immunology Drugs by Application (2012-2017)

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Market Share by Application in 2016

Table EMEA Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Market Share by Region (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Sales Share by Region (2012-2017)

Figure Sales Market Share of Ulcerative Colitis Immunology Drugs by Region (2012-2017)

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Market Share in 2016

Table EMEA Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table EMEA Ulcerative Colitis Immunology Drugs Revenue Share by Region (2012-2017)

Figure Revenue Market Share of Ulcerative Colitis Immunology Drugs by Region (2012-2017)

Figure EMEA Ulcerative Colitis Immunology Drugs Revenue Market Share Regions in 2016

Table EMEA Ulcerative Colitis Immunology Drugs Sales Price (USD/Pcs) by Region (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Revenue and Growth Rate (2012-2017)

Table Europe Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Type (2012-2017)

Table Europe Ulcerative Colitis Immunology Drugs Market Share by Type (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Market Share by Type in 2016

Table Europe Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Application (2012-2017)

Table Europe Ulcerative Colitis Immunology Drugs Market Share by Application (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Market Share by Application in 2016

Table Europe Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Countries (2012-2017)

Table Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Countries in 2016

Table Europe Ulcerative Colitis Immunology Drugs Revenue (Million USD) by Countries (2012-2017)

Table Europe Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries in 2016

Figure Germany Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure France Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure UK Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Russia Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Italy Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Benelux Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Middle East Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Middle East Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Middle East Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Type (2012-2017)

Table Middle East Ulcerative Colitis Immunology Drugs Market Share by Type (2012-2017)

Figure Middle East Ulcerative Colitis Immunology Drugs Market Share by Type (2012-2017)

Table Middle East Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Applications (2012-2017)

Table Middle East Ulcerative Colitis Immunology Drugs Market Share by Applications

(2012-2017)

Figure Middle East Ulcerative Colitis Immunology Drugs Sales Market Share by Application in 2016

Table Middle East Ulcerative Colitis Immunology Drugs Sales Volume (K Pcs) by Countries (2012-2017)

Table Middle East Ulcerative Colitis Immunology Drugs Sales Volume Market Share by Countries (2012-2017)

Figure Middle East Ulcerative Colitis Immunology Drugs Sales Volume Market Share by Countries in 2016

Table Middle East Ulcerative Colitis Immunology Drugs Revenue (Million USD) by Countries (2012-2017)

Table Middle East Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries in 2016

Figure Saudi Arabia Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Israel Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure UAE Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Iran Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Africa Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Type (2012-2017)

Table Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Type in 2016

Table Africa Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Application (2012-2017)

Table Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2012-2017)

Table Africa Ulcerative Colitis Immunology Drugs Sales Volume (K Pcs) by Countries (2012-2017)

Table Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Countries (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Countries in 2016

Table Africa Ulcerative Colitis Immunology Drugs Revenue (Million USD) by Countries (2012-2017)

Table Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries (2012-2017)

Figure Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Countries in 2016

Figure South Africa Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Nigeria Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Egypt Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Algeria Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Table Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Basic Information List

Table Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Basic Information List

Table Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table AbbVie Inc. Ulcerative Colitis Immunology Drugs Basic Information List

Table AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure AbbVie Inc. Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table UCBCares Ulcerative Colitis Immunology Drugs Basic Information List

Table UCBCares Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure UCBCares Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure UCBCares Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure UCBCares Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table AMGEN Ulcerative Colitis Immunology Drugs Basic Information List

Table AMGEN Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure AMGEN Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure AMGEN Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure AMGEN Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table Celltrion Healthcare Ulcerative Colitis Immunology Drugs Basic Information List

Table Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales Market Share in

EMEA (2012-2017)

Figure Celltrion Healthcare Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table Biogen Ulcerative Colitis Immunology Drugs Basic Information List

Table Biogen Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Biogen Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Biogen Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure Biogen Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Basic Information List

Table Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table ROCHE Ulcerative Colitis Immunology Drugs Basic Information List

Table ROCHE Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure ROCHE Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure ROCHE Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure ROCHE Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table Pfizer Inc. Ulcerative Colitis Immunology Drugs Basic Information List

Table Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate (2012-2017)

Figure Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales Market Share in EMEA (2012-2017)

Figure Pfizer Inc. Ulcerative Colitis Immunology Drugs Revenue Market Share in EMEA (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Ulcerative Colitis Immunology Drugs

Figure Manufacturing Process Analysis of Ulcerative Colitis Immunology Drugs

Figure Ulcerative Colitis Immunology Drugs Industrial Chain Analysis

Table Raw Materials Sources of Ulcerative Colitis Immunology Drugs Major Manufacturers in 2016

Table Major Buyers of Ulcerative Colitis Immunology Drugs

Table Distributors/Traders List

Figure EMEA Ulcerative Colitis Immunology Drugs Sales (K Pcs) and Growth Rate Forecast (2017-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Price (USD/Pcs) and Trend Forecast (2017-2022)

Table EMEA Ulcerative Colitis Immunology Drugs Sales (K Pcs) Forecast by Region (2017-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Market Share Forecast by Region (2017-2022)

Table EMEA Ulcerative Colitis Immunology Drugs Revenue (Million USD) Forecast by Region (2017-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Revenue Market Share Forecast by Region (2017-2022)

Table Europe Ulcerative Colitis Immunology Drugs Sales (K Pcs) Forecast by Countries (2017-2022)

Figure Europe Ulcerative Colitis Immunology Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Europe Ulcerative Colitis Immunology Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Europe Ulcerative Colitis Immunology Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table Middle East Ulcerative Colitis Immunology Drugs Sales (K Pcs) Forecast by Countries (2017-2022)

Figure Middle East Ulcerative Colitis Immunology Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Middle East Ulcerative Colitis Immunology Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Middle East Ulcerative Colitis Immunology Drugs Revenue Market Share

Forecast by Countries (2017-2022)

Table Africa Ulcerative Colitis Immunology Drugs Sales (K Pcs) Forecast by Countries (2017-2022)

Figure Africa Ulcerative Colitis Immunology Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Africa Ulcerative Colitis Immunology Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Africa Ulcerative Colitis Immunology Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table EMEA Ulcerative Colitis Immunology Drugs Sales (K Pcs) Forecast by Type (2017-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Market Share Forecast by Type (2017-2022)

Table EMEA Ulcerative Colitis Immunology Drugs Sales (K Pcs) Forecast by Application (2017-2022)

Figure EMEA Ulcerative Colitis Immunology Drugs Sales Market Share Forecast by Application (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

I would like to order

Product name: EMEA (Europe, Middle East and Africa) Ulcerative Colitis Immunology Drugs Market Report 2017

Product link: <https://marketpublishers.com/r/E523CB47640EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E523CB47640EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

